Leading Companies Fueling Growth and Innovation in the Stem Cell Therapy Market

The stem cell therapy sector is on the brink of significant expansion, driven by advancements in medical research and growing healthcare demands. As interest surges in regenerative medicine and innovative treatments, it is important to explore the market's projected growth, key players, and emerging trends shaping its future trajectory.

Projected Growth and Size of the Stem Cell Therapy Market
The stem cell therapy market is anticipated to expand rapidly, reaching a valuation of $14.6 billion by 2029. This represents a compound annual growth rate (CAGR) of 12.1% over the forecast period. Several factors contribute to this swift growth, including stronger government backing, an aging global population, increased investment in research and development, and rising healthcare spending. Key market trends focus on closely tracking advancements in mesenchymal stem cell therapies to leverage new innovations. Additionally, companies are encouraged to collaborate with or acquire others to accelerate product innovation and boost revenue streams. There is also a growing emphasis on developing induced pluripotent stem cell (iPSC)-derived natural killer cells for patient treatment. To stay competitive, firms should prioritize stem cell therapies for cancer, which provides an edge over somatic cell approaches, while also adopting artificial intelligence to enhance product quality, safety, and manufacturing efficiency.

Download a free sample of the stem cell therapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3399&type=smp

Top Companies Leading the Stem Cell Therapy Industry
The stem cell therapy landscape features several dominant players, including Fujifilm Holding Corporation, Thermo Fisher Scientific Inc., Takara Bio Inc., MEDIPOST Co., Ltd., Astellas Pharma Inc., and Catalent, Inc. Other major contributors include Pharmicell Co., Ltd., JCR Pharmaceuticals Co., Ltd., Stemedica Cell Technologies, Inc., Pluristem Technologies Ltd, and Becton dic*kinson Private Limited. The list also extends to Stem Cell Technologies India Pvt. Ltd, Cordlife India Pvt. Ltd, Lifecell International Pvt. Ltd, Stemcyte India Therapeutics Private Limited, Stempeutics Research Private Limited, and Anterogen Co., Ltd. Additional significant companies are Tonghua Dongbao Pharmaceutical Co, China Biologic Products Holdings Inc., Astrazenaca, Ablbio, Henlius, China Regenerative Medicine International, Innovent Biologics, Bio-Thera, Hisun Pharma, 3sbio, Beijing Shuanglu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Cellerix, Cellgenix, Nsgene, Tigenix, Renuron Group, Smart Cells, and Genenta Science. The sector also includes Amsterdam Molecular Therapeutics (Amt), Ark Therapeutics, Arthrogen Bv, Diamyd Medical Ab, Oxford Biomedica, Transgene, Mabion, Pure Biologics, Oncoarendi Therapeutics, Celon Pharma, Becton dic*kinson And Company, Osiris Therapeutics, Capricortherapeutics, Cellular Dynamics Discgenics, Takeda Pharmaceuticals, Kolon Tissue Gene, Athersys, Cyro-Cell International, Geron Corporation, Mesoblast Ltd, Astrom Biosciences Inc, Invitrogen, Cytori Therapeutics Inc, Nuvasive Inc, Bristol-Myers Squibb Aldagen Inc, Caladrius Biosciences Inc, Biogen Sa, Daiichi Sankyo Co. Ltd, Gamida Cell Ltd, Gilead Sciences, Inc., Novartis Ag, Pfizer, and Sanofi S.A.

Significant Acquisition Strengthens Position of Vertex Pharmaceuticals
In a major move in July 2022, Vertex Pharmaceuticals Inc., a biotechnology firm based in the US, acquired ViaCyte Pharma Inc. for $320 million. This strategic acquisition enhanced Vertex's capabilities in developing innovative cell replacement therapies for type 1 diabetes by providing access to additional technologies, stem cell lines, and manufacturing resources. ViaCyte Pharma, also US-based, specializes in creating novel stem cell-derived therapies targeting type 1 diabetes (T1D), and this deal has accelerated Vertex's ongoing developmental programs in this field.

View the full stem cell therapy market report:
https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Increasing Role of Collaborations in Shaping the Market
Strategic partnerships are becoming more prevalent among companies in the stem cell therapy sector. Such collaborations involve alliances between firms that do not directly compete but work together for mutual benefit. An example of this is the May 2022 partnership between SQZ Biotechnologies, a US-based biotech company, and STEMCELL Technologies Inc., a Canadian biotech firm. They joined forces to develop and commercialize a research-use-only (RUO) microfluidic intracellular delivery system built on SQZ's Cell Squeeze technology. This innovation offers enhanced cell engineering capabilities for preclinical research by efficiently delivering molecular cargoes to primary immune cell types. Both companies have demonstrated promising results using this system for advanced editing techniques such as mRNA and CRISPR/Cas9 in hematopoietic stem cells, showcasing important progress in cell engineering.

Detailed Segmentation of the Stem Cell Therapy Market
This report divides the stem cell therapy market into several key segments:
1) By Type: Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
2) By Cell Source: Adult Stem Cells, Induced Pluripotent Stem Cells (iPSCs), and Embryonic Stem Cells.
3) By Application: Covering Musculoskeletal Disorders and Wounds & Injuries, Cancer, Autoimmune Disorders, and Other conditions.
4) By End-Users: Including Hospitals and Clinics, Research Centers, and other institutional users.

Further Breakdowns Within Therapy Types
Within allogeneic stem cell therapy, cells are sourced from donors-either related or unrelated-and used to treat various conditions such as blood disorders and specific cancers. Common examples include umbilical cord blood stem cells and peripheral blood stem cells. Autologous stem cell therapy involves harvesting stem cells directly from the patient, often from bone marrow or adipose tissue. This approach is commonly applied to orthopedic injuries, cardiac diseases, and certain cancer treatments.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.